Pneumococcal Vaccine Market Growth, Size, Trends ,Analysis and Segment Forecast to 2034
Global Pneumococcal Vaccine Market Growth, Size, Trends Analysis - By Vaccine Type, By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25314 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
Pneumococcal Vaccine Market Introduction and Overview
According to SPER Market Research, the Global Pneumococcal Vaccine Market is estimated to reach USD 16.02 billion by 2034 with a CAGR of 6.43%.
The report includes an in-depth analysis of the Global Pneumococcal Vaccine Market, including market size and trends, product mix, Applications, and supplier analysis. The global Pneumococcal Vaccine Market was valued at USD 8.59 billion in 2024, and it is expected to rise at a 6.43% CAGR from 2025 to 2034. Investments in the pneumococcal vaccine market increase as more people and healthcare institutions realize how critical it is to prevent disease early in order to lower mortality rates. In addition to accessibility, both public and private organizations are now prioritizing the improvement of formulation and functionalities, which encourages market innovation.
By Vaccine Type Insights
In terms of global revenue, the pneumococcal conjugate vaccine segment led the market in 2024 and is expected to grow at the fastest rate during the forecast period. The Pneumococcal Conjugate Vaccine (PCV) aims to prevent pneumococcal disease, which is a major cause of death for children under five. PCVs are intended to protect against the most prevalent serotypes of Streptococcus pneumoniae, the bacterium that causes meningitis, pneumonia, and other severe infections. Increased vaccination rates are essential for preventing pneumococcal illness.
By Product Insights
In 2024, Prevnar 13 had the largest revenue share and led the market. Prevnar 13 and Prevnar 20 are among the vaccines marketed under the Prevnar name. These PCVs are made to guard against pneumococcal infections. Prevnar 13, a 13-valent pneumococcal conjugate vaccine, is designed to actively immunize adults 18 years of age and up against invasive diseases brought on by particular serotypes of Streptococcus pneumoniae. Additionally, it shields children of the same age group from otitis media brought on by these serotypes.
By End User Insights
In 2024, the market segment with the largest revenue share was the public sector. A number of factors contribute to the public sector's dominance in pneumococcal vaccine end-use, including hospitals, clinics, and healthcare facilities. The high incidence of the illness, government efforts to boost vaccination rates, and the affordability of public versus private sector immunization programs are some of these factors. One of the main causes is the increasing incidence of pneumococcal illnesses like meningitis, sepsis, and pneumonia.
Regional Insights
In 2024, the North American pneumococcal vaccine market held the largest market share worldwide. The market is driven by the active promotion of vaccination campaigns by government health agencies and organizations to prevent pneumococcal infections. The market is also expanding as a result of programs from national and government agencies, including the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), which strongly advise pneumococcal vaccination for children, older adults, and immunocompromised individuals.
Market Competitive Landscape
The leading companies in this sector comprise Pfizer, GlaxoSmithKline, and Merck & Co., which hold the most significant market share. These companies are consistently investing in the advancement of innovative vaccines to improve disease prevention. Additionally, forming strategic alliances with research institutions and healthcare providers has become essential for incorporating modern technologies and broadening distribution, allowing these firms to meet the rising demand for treatment alternatives. Thanks to regulatory backing and expedited approval procedures, which further encourage innovation and ease market entry, there is an increase in competition within the market.
Recent Developments:
In May 2024, in partnership with Gavi and WHO, the Serum Institute of India introduced its reasonably priced Pneumosil (PCV10) vaccine in ten African countries. Priced 40.4% less than rival vaccines, the product is expected to increase market share by 8.1%, bolstering the company's position in low-income markets.
In March 2024, Pfizer greatly increased access to its 20-valent pneumococcal vaccine (PCV20), which is intended for both adult and pediatric populations, in South Africa, Brazil, and India. Due to this launch, the company's vaccine division saw a 15.4% increase in revenue in the two
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Vaccine Type, By Product, By End Use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Serum Institute of India Pvt. Ltd., CSL Sanofi, GSK plc, Merck & Co., Inc., Pfizer Inc., Walvax Biotechnology Co., Ltd Beijing Minhai Biotechnology Co., Ltd |
Key Topics Covered in the Report
- Global Pneumococcal Vaccine Market Size (FY’2021-FY’2034)
- Overview of Global Pneumococcal Vaccine Market
- Segmentation of Global Pneumococcal Vaccine Market By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine)
- Segmentation of Global Pneumococcal Vaccine Market By Product (Prevnar 13, Synflorix, Pneumovax 23, VAXNEUVANCE, PNEUMOSIL)
- Segmentation of Global Pneumococcal Vaccine Market By End Use (Public Sector, Private Sector)
- Statistical Snap of Global Pneumococcal Vaccine Market
- Expansion Analysis of Global Pneumococcal Vaccine Market
- Problems and Obstacles in Global Pneumococcal Vaccine Market
- Competitive Landscape in the Global Pneumococcal Vaccine Market
- Details on Current Investment in Global Pneumococcal Vaccine Market
- Competitive Analysis of Global Pneumococcal Vaccine Market
- Prominent Players in the Global Pneumococcal Vaccine Market
- SWOT Analysis of Global Pneumococcal Vaccine Market
- Global Pneumococcal Vaccine Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs2.2.Market size estimation2.2.1.Top-down and Bottom-up approach2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTERs Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Pneumococcal Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Pneumococcal Vaccine Market
7.Global Pneumococcal Vaccine Market, By Vaccine Type (USD Million) 2021-2034
7.1.Pneumococcal Conjugate Vaccine7.2.Pneumococcal Polysaccharide Vaccine
8.Global Pneumococcal Vaccine Market, By Product (USD Million) 2021-2034
8.1.Prevnar 138.2.Synflorix8.3.Pneumovax 238.4.VAXNEUVANCE8.5.PNEUMOSIL8.6.Other Products
9.Global Pneumococcal Vaccine Market, By End User (USD Million) 2021-2034
9.1.Public Sector9.2.Private Sector
10.Global Pneumococcal Vaccine Market, (USD Million) 2021-2034
10.1.Global Pneumococcal Vaccine Market Size and Market Share
11.Global Pneumococcal Vaccine Market, By Region, (USD Million) 2021-2034
11.1.Asia-Pacific11.1.1.Australia11.1.2.China11.1.3.India11.1.4.Japan11.1.5.South Korea11.1.6.Rest of Asia-Pacific11.2.Europe11.2.1.France11.2.2.Germany11.2.3.Italy11.2.4.Spain11.2.5.United Kingdom11.2.6.Rest of Europe11.3.Middle East and Africa11.3.1.Kingdom of Saudi Arabia11.3.2.United Arab Emirates11.3.3.Qatar11.3.4.South Africa11.3.5.Egypt11.3.6.Morocco11.3.7.Nigeria11.3.8.Rest of Middle-East and Africa11.4.North America11.4.1.Canada11.4.2.Mexico11.4.3.United States11.5.Latin America11.5.1.Argentina11.5.2.Brazil11.5.3.Rest of Latin America
12.Company Profile
12.1.Serum Institute of India Pvt. Ltd12.1.1.Company details12.1.2.Financial outlook12.1.3.Product summary12.1.4.Recent developments12.2.CSL12.2.1.Company details12.2.2.Financial outlook12.2.3.Product summary12.2.4.Recent developments12.3.Sanofi12.3.1.Company details12.3.2.Financial outlook12.3.3.Product summary12.3.4.Recent developments12.4.GSK plc12.4.1.Company details12.4.2.Financial outlook12.4.3.Product summary12.4.4.Recent developments12.5.Merck & Co., Inc12.5.1.Company details12.5.2.Financial outlook12.5.3.Product summary12.5.4.Recent developments12.6.Pfizer Inc12.6.1.Company details12.6.2.Financial outlook12.6.3.Product summary12.6.4.Recent developments12.7.Walvax Biotechnology Co., Ltd12.7.1.Company details12.7.2.Financial outlook12.7.3.Product summary12.7.4.Recent developments12.8.Beijing Minhai Biotechnology Co., Ltd12.8.1.Company details12.8.2.Financial outlook12.8.3.Product summary12.8.4.Recent developments
12.9.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Pneumococcal Vaccine Market is projected to reach USD 16.02 by 2034, growing at a CAGR of 6.43% during the forecast period.
Pneumococcal Vaccine Market size from 2025. The Market is expected to reach USD 16.02 by 2034, at a CAGR of 6.43% during the forecast period.
Pneumococcal Vaccine Market CAGR of 6.43% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Pneumococcal Vaccine Market size is USD 16.02 from 2025 to 2034.
Pneumococcal Vaccine Market covered By Vaccine Type, By Product, By End Use
The North America is anticipated to have the highest Market share in the Pneumococcal Vaccine Market .
"Serum Institute of India Pvt. Ltd., CSL
Sanofi, GSK plc, Merck & Co., Inc., Pfizer Inc., Walvax Biotechnology Co., Ltd
Beijing Minhai Biotechnology Co., Ltd
"
"
The report includes an in-depth analysis of the Global Pneumococcal Vaccine Market, including market size and trends, product mix, Applications, and supplier analysis."
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
